Peter Powchik Insider Trading $REGN REGENERON PHARMACEUTICALS, INC.
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Peter Powchik.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Peter Powchik. Peter Powchik is SVP Clin Devel & Reg Affairs in REGENERON PHARMACEUTICALS INC ($REGN) and SVP Clinical Development in REGENERON PHARMACEUTICALS INC ($REGN) and SVP Clinical Development & Reg in REGENERON PHARMACEUTICALS INC ($REGN) and SVP, Clinical Development in REGENERON PHARMACEUTICALS INC ($REGN).
Peter Powchik in REGENERON PHARMACEUTICALS, INC.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Peter Powchik: SVP Clin Devel & Reg Affairs, SVP Clinical Development & Reg, SVP Clinical Development, SVP, Clinical Development
Holdings: 2,459 shares
Current Value: $879,560
Latest Transaction: Dec 19 2016
$REGN Market Capitalization: $37.03B
$REGN Previous Close: $357.69
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of Peter Powchik in REGENERON PHARMACEUTICALS, INC.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 23 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 100.32 | 5,753 | 577,141 | 64,398 | 70.2 K to 64.4 K (-8.20 %) |
| Feb 23 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 100.32 | 2,511 | 251,904 | 70,151 | 72.7 K to 70.2 K (-3.46 %) |
| Feb 23 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Buy | M | 16.80 | 15,000 | 252,000 | 72,662 | 57.7 K to 72.7 K (+26.01 %) |
| Feb 23 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 100.32 | 9,158 | 918,731 | 57,662 | 66.8 K to 57.7 K (-13.71 %) |
| Feb 23 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 100.32 | 5,558 | 557,579 | 66,820 | 72.4 K to 66.8 K (-7.68 %) |
| Feb 23 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Buy | M | 21.92 | 25,438 | 557,601 | 72,378 | 46.9 K to 72.4 K (+54.19 %) |
| Feb 23 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 100.32 | 7,347 | 737,051 | 46,940 | 54.3 K to 46.9 K (-13.53 %) |
| Feb 23 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 100.32 | 4,050 | 406,296 | 54,287 | 58.3 K to 54.3 K (-6.94 %) |
| Feb 23 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Buy | M | 20.32 | 20,000 | 406,400 | 58,337 | 38.3 K to 58.3 K (+52.17 %) |
| Feb 23 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 100.32 | 18,530 | 1,858,930 | 38,337 | 56.9 K to 38.3 K (-32.58 %) |
| Feb 23 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 100.32 | 7,705 | 772,966 | 56,867 | 64.6 K to 56.9 K (-11.93 %) |
| Feb 23 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Buy | M | 15.64 | 49,428 | 773,054 | 64,572 | 15.1 K to 64.6 K (+326.39 %) |
| Dec 20 2011 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | A | 52.03 | 30,079 | 1,565,010 | 30,079 | |
| Dec 20 2011 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | A | 16.80 | 30,000 | 504,000 | 45,000 | |
| Dec 20 2011 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | A | 52.03 | 1,921 | 99,950 | 1,921 | |
| Aug 02 2011 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | M | 15.64 | 15,144 | 236,852 | 10,428 | |
| Aug 02 2011 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Buy | M | 15.64 | 15,144 | 236,852 | 15,144 | 0 to 15.1 K |
| Jul 26 2011 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | M | 15.64 | 25,000 | 391,000 | 49,428 | |
| Jul 26 2011 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 54.74 | 7,400 | 405,076 | 0 | 7.4 K to 0 (-100.00 %) |
| Jul 26 2011 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 55.19 | 3,577 | 197,415 | 7,400 | 11 K to 7.4 K (-32.59 %) |
| Jul 26 2011 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 56.26 | 7,074 | 397,983 | 10,977 | 18.1 K to 11 K (-39.19 %) |
| Jul 26 2011 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 56.26 | 6,949 | 390,951 | 18,051 | 25 K to 18.1 K (-27.80 %) |
| Jul 26 2011 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Buy | M | 15.64 | 25,000 | 391,000 | 25,000 | 0 to 25 K |
| Dec 20 2010 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | A | 30.63 | 28,736 | 880,184 | 28,736 | |
| Dec 20 2010 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | A | 30.63 | 3,264 | 99,976 | 3,264 | |
| Dec 22 2009 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | A | 21.25 | 14,543 | 309,039 | 14,543 | |
| Dec 22 2009 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | A | 21.25 | 5,457 | 115,961 | 5,457 | |
| Dec 18 2008 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP, Clinical Devel ... | Option Exercise | A | 16.80 | 15,000 | 252,000 | 15,000 | |
| Dec 18 2008 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP, Clinical Devel ... | Option Exercise | A | 16.80 | 5,000 | 84,000 | 5,000 | |
| Dec 19 2007 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP, Clinical Devel ... | Option Exercise | A | 21.92 | 25,438 | 557,601 | 25,438 | |
| Dec 19 2007 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP, Clinical Devel ... | Option Exercise | A | 21.92 | 4,562 | 99,999 | 4,562 | |
| Dec 20 2006 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP, Clinical Devel ... | Option Exercise | A | 20.32 | 20,000 | 406,400 | 20,000 | |
| Oct 03 2006 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP, Clinical Devel ... | Option Exercise | A | 15.64 | 74,428 | 1,164,054 | 74,428 | |
| Oct 03 2006 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP, Clinical Devel ... | Option Exercise | A | 15.64 | 25,572 | 399,946 | 25,572 |